Abstracts tagged "SLE"

Abstract Number: 649 • 2019 ACR/ARP Annual Meeting
Potentially Reversible Associations with Fatigue in SLE Patients – Results from a Single-centre Study
Christina Duesing¹, Gamal Chehab ², Jutta Richter ³, Oliver Sander ⁴, Rebecca Fischer-Betz ⁵, Benedikt Ostendorf ¹, Hasan Acar ¹, Ralph Brinks ⁶ and Matthias Schneider ⁵, ¹Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, Duesseldorf, Nordrhein-Westfalen, Germany, ²Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ³Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ⁴Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, ⁵Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Fatigue is the most common symptom in SLE patients with a strong impact on patients’ reported quality of life. The cause of fatigue is…
Abstract Number: 884 • 2019 ACR/ARP Annual Meeting
Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice
Dario Ferri ¹, Yuriy Baglaenko ², Kieran Manion ³, Carolina Munoz-Grajales ⁴ and Joan Wither⁵, ¹University Health Network, Toronto, ON, Canada, ²Brigham Woman's Hospital, Boston, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University Health Network, Toronto, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Interferon-alpha (IFNα) is elevated in Systemic Lupus Erythematosus (SLE) and is thought to play a central role in its pathogenesis. Amongst IFNα’s many effects…
Abstract Number: 1560 • 2019 ACR/ARP Annual Meeting
Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus Combined EBV/CMV Viremia
Rui Su¹, Yue Liu ¹, Xinyu Zheng ¹, Xiao-feng Li ² and Cai-hong Wang ³, ¹Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, Tai Yuan, China (People's Republic), ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, TaiYuan, China (People's Republic), ³The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic)
Background/Purpose: Infection is common and is one of the leading causes of morbidity and mortality in Systemic Lupus Erythematosus (SLE) patients . Excessive using glucocorticoid…
Abstract Number: 1829 • 2019 ACR/ARP Annual Meeting
Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Melissa E. Munroe¹, Sarah Kleckner ¹, Wade DeJager ¹, Susan R. Macwana ¹, Joel Guthridge ², Eldon Jupe ³, Mohan Purushothaman ³, Sanjiv Sharma ³, Nancy Redinger ¹, Teresa Aberle ¹, Stan Kamp ¹, Cristina Arriens ², Eliza F. Chakravarty ², Joan T. Merrill ⁴ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is marked by altered immune regulation linked to waxing and waning clinical disease activity. This study seeks to verify the alteration of inflammatory…
Abstract Number: 2547 • 2019 ACR/ARP Annual Meeting
Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use
Anca Askanase¹, Dharani Munirathinam ², Enxu Zhao ², Julie Zhu ², Erin Connolly-Strong ² and Richard Furie ³, ¹Columbia University Medical Center, New York, NY, ²Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ³Northwell Health, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI) is a naturally sourced complex mixture of adrenocorticotropic hormone (ACTH1-39) analogues and other pituitary peptides that stimulates endogenous corticosteroid (CS)…
Abstract Number: 658 • 2019 ACR/ARP Annual Meeting
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
Sarah Dyball¹, John Reynolds ², Hector Chinoy ², Tracy Briggs ², Sahena Haque ³, Eoghan McCarthy ⁴, Ellen Bruce ⁵, Ariane Herrick ⁶, Ian Bruce ⁷ and Ben Parker ⁸, ¹University of Manchester, Manchestser, United Kingdom, ²University of Manchester, Manchester, United Kingdom, ³University Hospital South Manchester, Manchester, United Kingdom, ⁴Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Central Manchester University Hospitals, Manchester, United Kingdom, ⁶Salford Royal Foundation Trust, Manchester, United Kingdom, ⁷University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁸University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom, Manchester, United Kingdom
Background/Purpose: Connective tissue diseases (CTDs) are a heterogeneous group of diseases with overlapping clinical features and shared immunopathology. In routine practice, a clinician diagnosis is…
Abstract Number: 897 • 2019 ACR/ARP Annual Meeting
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Medha Barbhaiya¹, Sarah Chen ², Candace Feldman ³, Hongshu Guan ³, Brendan Everett ⁴ and Karen Costenbader ⁴, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Brigham and Women's Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Despite similar myocardial infarction risks in SLE and diabetes mellitus (DM) patients, individuals with SLE enrolled in Medicaid had substantially higher rates of coronary…
Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Oshrat Tayer-Shifman¹, Robin Green ², Dorcas Beaton ³, Lesley Ruttan ², Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ², Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³St. Michael's Hospital, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…
Abstract Number: 1844 • 2019 ACR/ARP Annual Meeting
The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Alexandra Watts¹, Desiree Azizoddin ², Shadi Gholizadeh ³, Sarah Mills ⁴, Geraldine Zamora ⁵, Daniel Wallace ⁶, Meenakshi Jolly ⁷, Michael Weisman ⁸ and Perry Nicassio ⁹, ¹University of California, Los Angeles, Los Angeles, CA, ²Dana-Farber Cancer Institute, Boston, MA, ³McGill University, Montreal, Canada, ⁴Lineberger Comprehensive Cancer Center, Chapel Hill, NC, ⁵Manila Doctors Hospital, Manila, Philippines, ⁶Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁷Rush University Medical Center, Chicago, IL, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: It is well known that patients with SLE are often afflicted with deficits in quality of life and problems with physical impairment and psychosocial…
Abstract Number: 2549 • 2019 ACR/ARP Annual Meeting
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials
Maria Pitsui ¹, Orestis Papasouliotis², Colm Farrell ¹, Pascal Girard ², Oezkan Yalkinoglu ³ and Cristina Vazquez-Mateo ⁴, ¹ICON Plc, Dublin, Ireland, ²Merck Institute for Pharmacometrics, Lausanne, Switzerland, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research and Development Institute, Inc., Billerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL and has been shown to reduce SLE disease activity. The aim of the analysis was…
Abstract Number: 662 • 2019 ACR/ARP Annual Meeting
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Brooke Williams¹, Bridget Muckian ¹, Claire Dykas ², Christine Peschken ³, Richard Furie ⁴, Elena Massarotti ⁵, Vanja sikirica ⁶, Steven Gilbert ⁷, Martin Hodge ⁷ and Peter Lipsky ⁸, ¹AMPEL BioSolutions, Charlottesville, VA, ²AmpelBioSolutions, Charlottesville, VA, ³University of Manitoba, Winnepeg, Canada, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁶Pfizer, Boston, MA, ⁷Pfizer, Boston, ⁸AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide important data about the impact of a disease on an individual and/or the quality of the response to…
Abstract Number: 942 • 2019 ACR/ARP Annual Meeting
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Daniel Wallace¹, Roberta Alexander ², Tyler O'Malley ³, Arezou Khosroshahi ⁴, Mehrnaz Hojjati ⁵, Konstantinos Loupasakis ⁶, Jeffrey Alper ⁷, Yvonne Sherrer ⁷, Maria Fondal ⁷, Rajesh Kataria ⁸, Tami Powell ², Claudia Ibarra ², Sonali Narain ⁹, Elena Massarotti ¹⁰, Arthur Weinstein ² and Thierry Dervieux ², ¹Cedars Sinai Medical Center/UCLA, Los Angeles, CA, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA, ⁴Emory University, Atlanta, GA, ⁵Department of Rheumatology, Loma Linda University, Loma Linda, CA, ⁶MedStar Washington Hospital Center, Department of Rheumatology, Washington, DC, ⁷BendCare Rheumatology, Naples, FL, ⁸Southern Ohio Rheumatology, Wheelersburg, OH, ⁹Northwell Health, Great Neck, Long Island, NY, ¹⁰Brigham and Women's Hospital/Harvard Medical School, Boston, MA
Background/Purpose: Cell-Bound Complement Activation Products (CB-CAPs) in multianalyte assay panel (MAP) is a diagnostic immunology laboratory test with established clinical validity in distinguishing systemic lupus…
Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting
Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India
Sarit Sekhar Pattanaik¹, Hafis Muhammed ², Amita Aggarwal ³, Able Lawrence ⁴, Vikas Agarwal ², Durga P Misra ², Latika Gupta ⁴ and Ramnath Misra ⁴, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²SGPGI, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India
Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…
Abstract Number: 1864 • 2019 ACR/ARP Annual Meeting
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Gabriela Schmajuk¹, Zara Izadi ², Michael Evans ³ and Jinoos Yazdany ⁴, ¹UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ²UCSF Division of Rheumatology, San Francisco, ³University of California San Francisco, San Francisco, ⁴UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Although multiple national quality measures focus on the management and safety of rheumatoid arthritis, few measures address the care of patients with SLE. We…
Abstract Number: 2555 • 2019 ACR/ARP Annual Meeting
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Konstantinos Tselios¹, Dafna Gladman ², Shadi Akhtari ³, Paula Harvey ³, Kate Hanneman ⁴ and Murray Urowitz ⁵, ¹University Health Network, University of Toronto, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial-induced cardiomyopathy (AMIC) is a hypertrophic cardiomyopathy with conduction system disorders, cardiac biomarker abnormalities and a short-term mortality of 45%. Data on the reversibility…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].